In yesterday’s Wall Street session, Allogene Therapeutics Inc (NASDAQ:ALLO) shares traded at $3.42, down -2.29% from the previous session.
ALLO stock price is now 33.23% away from the 50-day moving average and 4.72% away from the 200-day moving average. The market capitalization of the company currently stands at $714.03M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $11, Piper Sandler recently initiated with Overweight rating for Allogene Therapeutics Inc (NASDAQ: ALLO). , while ‘Guggenheim’ rates the stock as ‘Neutral’
In other news, MESSEMER DEBORAH M., Director sold 18,641 shares of the company’s stock on Jun 18 ’24. The stock was sold for $42,488 at an average price of $2.28. Upon completion of the transaction, the Director now directly owns 166,765 shares in the company, valued at $0.57 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 30 ’24, Director Humer Franz B sold 11,200 shares of the business’s stock. A total of $26,181 was realized by selling the stock at an average price of $2.34. This leaves the insider owning 255,253 shares of the company worth $0.87 million. A total of 34.53% of the company’s stock is owned by insiders.
During the past 12 months, Allogene Therapeutics Inc has had a low of $2.01 and a high of $5.78. As of last week, the company has a debt-to-equity ratio of 0.21, a current ratio of 12.80, and a quick ratio of 12.80. The fifty day moving average price for ALLO is $2.574 and a two-hundred day moving average price translates $3.26595 for the stock.
The latest earnings results from Allogene Therapeutics Inc (NASDAQ: ALLO) was released for 2024-03-31. The net profit margin was -223140.00% and return on equity was -55.06% for ALLO. The company reported revenue of $22000.0 for the quarter, compared to $30000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -26.67 percent.
